5 › 5.1 › 5.1.1
5.1.1 Natriuretic peptides
Pages 22–24 · open in PDF
Recommendations in this section
- Class ILevel CIn patients with suspected HF, the following laboratory tests are recommended when screening for comorbidities: full blood count, kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin).
- Class ILevel CNatriuretic peptide measurement is recommended in patients with suspected HF (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic peptide level).
- Class ILevel CA 12-lead ECG is recommended in patients with suspected HF.
- Class ILevel CChest radiography (X-ray) is recommended in patients with suspected HF.
- Class ILevel CTransthoracic echocardiogram is recommended in patients with suspected HF to confirm the diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of HF.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 22 · PDF
22 Symptoms and signs of heart failure
Table 8 New York Heart Association functional classification based on severity of symptoms and physical activity
Elevated jugular venous pressure
Paroxysmal nocturnal dyspnoea
Third heart sound (gallop rhythm)
Reduced exercise tolerance
Laterally displaced apical impulse
Severity of symptoms and physical activity
No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue, or palpitations.
Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue, or palpitations.
Fatigue, tiredness, increased
time to recover after exercise
Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in undue breathlessness, fatigue, or palpitations.
Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any
Weight loss (in advanced HF)
physical activity is undertaken, discomfort is
Confusion (especially in the
Peripheral oedema (ankle, sacral,
NYHA, New York Heart Association.
Tachypnoea Cheyne–Stokes respiration Hepatomegaly Cold extremities Oliguria Narrow pulse pressure
HF, heart failure. a Elderly patients may present with more atypical symptoms of HF. b Breathlessness on bending forward/flexing the body.
5.1.1. Natriuretic peptides Adverse clinical events often occur soon after a new presentation of HF in the community; therefore, timely diagnosis and initiation of treatment are essential. Natriuretic peptide testing is recommended to support the diagnosis of HF and improves efficiency by avoiding unnecessary echocardiography and/or specialist assessment.146–150 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the most widely used natriuretic peptide in the management of HF in Europe and has two key advantages: better stability at room temperature, enabling reliable testing in both hospital and community settings; and unaltered results despite treatment with ARNIs, which affect B-type natriuretic peptide (BNP) degradation.149,150 However, testing for NT-proBNP is not universally available, and some regions employ BNP or mid-regional pro-atrial natriuretic peptide (MR-proANP) testing. The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure recommended a single natriuretic
peptide threshold to ‘rule out’ HF (<125 pg/mL for NT-proBNP, <35 pg/mL; for BNP, <40 pg/mL; for MR-proANP). Single natriuretic peptide rule-out thresholds have the advantage of simplicity; however, natriuretic peptide levels are strongly related to age and lack specificity in older people.151 More than 75% of a healthy population >80 years were found to exceed the 125 pg/mL NT-proBNP threshold.152–156 The HFA-ESC consensus statement on NT-proBNP testing recommends introducing age-related thresholds determined from the 95th percentile of the Generation Scotland cohort to improve specificity and reduce unnecessary demand on echocardiography and HF services.157 The suggested age-adjusted NT-proBNP levels, above which HF is ‘likely’ in the outpatient setting, were ≥125 pg/mL for those aged <50 years, ≥250 pg/mL between 50 and 75 years, and ≥500 pg/mL over 75 years.151,157 Currently there are insufficient data for determining age-specific BNP cut-offs. For the diagnosis of HFpEF, natriuretic peptide interpretation may be challenging as a variety of conditions associated with HFpEF affect natriuretic peptide levels (Table 9).158 Especially obesity is associated with lower cut-off values for natriuretic peptides, and caution is advised when interpreting natriuretic peptide levels in obese patients.158–160 Reduced kidney function has been shown to be associated with higher NT-proBNP levels, although NT-proBNP measurements should not be disregarded in the setting of kidney dysfunction.161,162 Furthermore, many other factors can elevate natriuretic peptide levels (Table 9). Clinicians must consider these factors in conjunction with clinical assessment and investigation findings when interpreting natriuretic peptide measurements; however, the higher the natriuretic peptide level the greater the likelihood of HF as the diagnosis. Natriuretic peptides also provide important prognostic information, enabling rapid triage of high-risk patients. Primary care data from England demonstrate that patients with HF and NT-proBNP levels exceeding 2000 pg/mL exhibit a two-fold increased risk of early HFH. Accordingly, expedited specialist assessment of this high-risk cohort is warranted.163
Page 23 · PDF
Figure 4 Diagnostic algorithm for chronic heart failure presenting in the outpatient or community setting. BNP, B-type natriuretic peptide; CXR, chest X-ray; ECG, electrocardiogram; HbA1c, glycated haemoglobin; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; POCUS, point-of-care ultrasound; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. a Full blood count, kidney function, electrolytes, UACR, liver function, thyroid function, HbA1c, lipids, and iron status (TSAT and ferritin). b Examination by POCUS may aid in diagnosis although echocardiography is recommended. cNatriuretic peptides may be false low in certain settings (Table 9). dPreferable performed within 2 weeks if NT-proBNP >2000 pg/mL.
Page 24 · PDF
required in the assessment of kidney function.164 UACR is independent of glomerular filtration rate (GFR), and severe albuminuria (grade A3) may be present despite GFR ≥90 mL/min/ 1.73 m2. UACR has strong independent prognostic value for patients with HF.165,166 Albuminuria is a potentially treatable and reversible disorder, amenable to medications also used in HF, including ACE-Is/ARNIs/ARBs, MRAs, and SGLT2-Is.167
Table 9 Causes for increase or decrease in natriuretic peptide levels Causes for increased natriuretic peptide levels Acute coronary syndrome Advanced agea Atrial fibrillation Cardiac contusion Critical illness Female sex Kidney dysfunction
LV hypertrophy Myocarditis
In patients with suspected HF, the following laboratory tests are recommended when
screening for comorbidities: full blood count,
kidney function (eGFR and UACR), electrolytes, liver function, thyroid function, HbA1c, lipids,
Pulmonary embolism Pulmonary hypertension
and iron status (TSAT and ferritin).168
Natriuretic peptide measurement is (interpreted in relation to patient age, obesity, and other factors known to affect natriuretic
Severe endocrine dysfunction Severe infections (including pneumonia and sepsis)
A 12-lead ECG is recommended in patients with
Severe metabolic acidosis and diabetic ketoacidosis
Chest radiography (X-ray) is recommended in
patients with suspected HF.
in patients with suspected HF to confirm the
African ancestry ARNI /ACE-I/ARB
diagnosis, differentiate between HF phenotypes and aid in identifying the underlying aetiology of
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; RV, right ventricular; SGLT2-I, sodium–glucose co-transporter 2 inhibitor. a See Figure 4. b ARNI may raise BNP levels.
5.1.2. Other laboratory tests Basic investigations, such as serum urea and electrolytes, creatinine, full blood count, glycated haemoglobin, lipids, iron status [transferrin saturation (TSAT) and ferritin], liver and thyroid function tests, are recommended to assess for and evaluate comorbidities, to provide prognostic information, and to guide potential therapy. Urine albumin-to-creatinine ratio (UACR) has been added to the initial baseline investigations, because the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise that both estimated glomerular filtration rate (eGFR) and UACR (graded A1, <30 mg/g; A2, 30–300 mg/g; A3, >300 mg/g) are
ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation; UACR, urine albumin-to-creatinine ratio. a Class of recommendation. b Level of evidence. c See Figure 4 for age-adjusted cut-offs for NT-proBNP levels, and Table 9 for factors affecting natriuretic peptide levels.
5.2. Heart failure phenotypes based on left ventricular ejection fraction Echocardiography provides evaluations of both systolic and diastolic function and valvular function and enables the distinction between HF (stage C) phenotypes based on LVEF.
5.2.1. Heart failure with reduced ejection fraction The diagnosis of HFrEF requires the following criteria: (i) Presence of current or prior symptoms and/or signs of HF (Table 7) (ii) LVEF <50%. Elevated natriuretic peptides strongly support the diagnosis of HFrEF in the presence of symptoms, and may aid in the
Transthoracic echocardiogram is recommended
Causes for decreased natriuretic peptide levels
peptide levelc).146–148,151–153,169
recommended in patients with suspected HF
Recommendation Table 3 — Recommendations for diagnostic investigations in all patients with suspected heart failure (see Evidence Tables 17–19)